To some extent, the hypothesis could be supported by the enhancement of ERK or MK2 signaling pathways in cancers, such as prostate cancer and bladder cancer, which presented down-regulation of PDE4 expression34,35. The gene discussed is PDE4A; the disease is prostate carcinoma.